OBJECT: The development of multimodality approaches for the treatment of cerebral arteriovenous malformations (AVMs), including microsurgery, endovascular therapy, and radiosurgery, has shifted modern treatment paradigms in the last 10 years. This study examines these changes in detail from a nationwide perspective. METHODS: The authors examined data from 2001 to 2009 in the Nationwide Inpatient Sample (NIS) database, and they assessed the safety, quality, and cost-effectiveness, including the total number of discharges, discharge proportion, length of stay, and hospital charges. The authors also examined patient demographics (including age, sex, income level, and insurance), hemorrhage status at presentation, and trends in open surgical and endovascular treatment. RESULTS: A total of 33,997 inpatient admissions for patients with a primary diagnosis of intracranial AVM were identified, with a mean of 4191 patients admitted annually. The mean hospital charges increased 2-fold over the study period without significant differences in outcomes. There were substantial differences between surgical, endovascular, radiosurgical, and multimodality treatments. The proportion of AVMs treated microsurgically remained stable over this period, while the proportion treated endovascularly dramatically increased in size, and the data demonstrate important patient-level distinctions among groups. Outcomes and complication profiles were significantly different between treatment modalities and were impacted by age and hemorrhage status. CONCLUSIONS: Charges associated with treatment of cerebral AVMs to the payer and society have increased dramatically over the first decade of the 21st century without clear improvements in quality parameters. However, analysis of the 3 primary treatment modalities has demonstrated differences and warrants further investigation to understand which patient population would benefit maximally from each. Unfortunately, with only imprecise measurements of quality in health care delivery, it remains imperative to develop national databases in which parameters, such as survival, functional outcomes, quality of life, and complication rates, can be assessed to examine the value of care delivered in a more meaningful way. Demonstrating an ever-increasing value of delivered health care will be imperative in our evolving health care system.
OBJECT: The development of multimodality approaches for the treatment of cerebral arteriovenous malformations (AVMs), including microsurgery, endovascular therapy, and radiosurgery, has shifted modern treatment paradigms in the last 10 years. This study examines these changes in detail from a nationwide perspective. METHODS: The authors examined data from 2001 to 2009 in the Nationwide Inpatient Sample (NIS) database, and they assessed the safety, quality, and cost-effectiveness, including the total number of discharges, discharge proportion, length of stay, and hospital charges. The authors also examined patient demographics (including age, sex, income level, and insurance), hemorrhage status at presentation, and trends in open surgical and endovascular treatment. RESULTS: A total of 33,997 inpatient admissions for patients with a primary diagnosis of intracranial AVM were identified, with a mean of 4191 patients admitted annually. The mean hospital charges increased 2-fold over the study period without significant differences in outcomes. There were substantial differences between surgical, endovascular, radiosurgical, and multimodality treatments. The proportion of AVMs treated microsurgically remained stable over this period, while the proportion treated endovascularly dramatically increased in size, and the data demonstrate important patient-level distinctions among groups. Outcomes and complication profiles were significantly different between treatment modalities and were impacted by age and hemorrhage status. CONCLUSIONS: Charges associated with treatment of cerebral AVMs to the payer and society have increased dramatically over the first decade of the 21st century without clear improvements in quality parameters. However, analysis of the 3 primary treatment modalities has demonstrated differences and warrants further investigation to understand which patient population would benefit maximally from each. Unfortunately, with only imprecise measurements of quality in health care delivery, it remains imperative to develop national databases in which parameters, such as survival, functional outcomes, quality of life, and complication rates, can be assessed to examine the value of care delivered in a more meaningful way. Demonstrating an ever-increasing value of delivered health care will be imperative in our evolving health care system.
Authors: Caleb Rutledge; Jeffrey Nelson; Alex Lu; Peyton Nisson; Soren Jonzzon; Ethan A Winkler; Daniel Cooke; Adib A Abla; Michael T Lawton; Helen Kim Journal: Acta Neurochir (Wien) Date: 2019-11-23 Impact factor: 2.216
Authors: Santosh B Murthy; Alexander E Merkler; Setareh Salehi Omran; Gino Gialdini; Aaron Gusdon; Benjamin Hartley; David Roh; Halinder S Mangat; Costantino Iadecola; Babak B Navi; Hooman Kamel Journal: Neurology Date: 2017-04-19 Impact factor: 9.910
Authors: Jina Kim; Zhifei Sun; Harold J Leraas; Uttara P Nag; Ehsan Benrashid; Alexander C Allori; Waleska M Pabon-Ramos; Henry E Rice; Cynthia K Shortell; Elisabeth T Tracy Journal: Pediatr Surg Int Date: 2016-11-22 Impact factor: 1.827
Authors: Alexandra S Reynolds; Monica L Chen; Alexander E Merkler; Abhinaba Chatterjee; Iván Díaz; Babak B Navi; Hooman Kamel Journal: Cerebrovasc Dis Date: 2019-08-21 Impact factor: 2.762
Authors: Hormuzdiyar H Dasenbrock; David J Cote; Yuri Pompeu; Viren S Vasudeva; Timothy R Smith; William B Gormley Journal: BMC Neurol Date: 2017-06-26 Impact factor: 2.474
Authors: Mariusz Hofman; Tomasz Jamróz; Izabela Kołodziej; Jakub Jaskólski; Aleksandra Ignatowicz; Izabela Jakutowicz; Nikodem Przybyłko; Damian Kocur; Jan Baron Journal: Pol J Radiol Date: 2018-05-29
Authors: Tim E Darsaut; Elsa Magro; Jean-Christophe Gentric; André Lima Batista; Chiraz Chaalala; David Roberge; Michel W Bojanowski; Alain Weill; Daniel Roy; Jean Raymond Journal: Trials Date: 2015-11-04 Impact factor: 2.279